Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 1,789 shares, a decrease of 67.3% from the April 15th total of 5,479 shares. Based on an average daily trading volume, of 102,108 shares, the days-to-cover ratio is currently 0.0 days.
Tevogen Bio Price Performance
Shares of TVGNW stock traded down $0.00 on Friday, reaching $0.04. 198,391 shares of the company’s stock were exchanged, compared to its average volume of 129,485. The company’s fifty day simple moving average is $0.03 and its 200 day simple moving average is $0.04. Tevogen Bio has a 52 week low of $0.03 and a 52 week high of $0.08.
Tevogen Bio Company Profile
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Read More
- Five stocks we like better than Tevogen Bio
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
